Lataa...
Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity
Adeno-associated virus (AAV) vector liver-directed gene therapy (GT) for hemophilia B (HB) is limited by a vector dose–dependent hepatotoxicity. Recently, this obstacle has been partially circumvented by the use of a hyperactive factor IX (FIX) variant, R338L (Padua), which has an 8-fold increased s...
Tallennettuna:
| Julkaisussa: | JCI Insight |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
American Society for Clinical Investigation
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6675543/ https://ncbi.nlm.nih.gov/pubmed/31219805 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.128683 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|